What's Happening?
A recent study published in the Journal of Cachexia, Sarcopenia and Muscle has found that rapamycin, a drug used by some for its potential longevity benefits, may reduce the health gains from exercise. Rapamycin, approved by the FDA for preventing organ-transplant
rejection, has been used off-label by longevity enthusiasts. The study, led by Brad Stanfield, involved older adults in New Zealand and showed that those taking rapamycin gained less strength and physical function from exercise compared to those on a placebo. The findings suggest rapamycin may interfere with muscle growth and recovery.
Why It's Important?
This study is significant as it challenges the perception of rapamycin as a beneficial supplement for longevity, particularly when combined with exercise. Exercise is a well-established method for improving health and longevity, and any interference with its benefits could have implications for those using rapamycin. The findings may influence public health recommendations and the decisions of individuals considering rapamycin for longevity purposes. It also highlights the need for further research into the interactions between potential longevity drugs and exercise.
What's Next?
Further research is needed to explore the interactions between rapamycin and exercise, including different dosing schedules and their effects on muscle growth and recovery. The study's findings may prompt healthcare professionals to reconsider recommendations for rapamycin use among older adults. Additionally, the results could lead to more comprehensive studies to better understand the drug's impact on human health and longevity.
